

# **Global Pharmaceutical Outlook 2024–2050**

Strategic Analysis & India's Leadership Roadmap

Article written by Prof. Arun Sehgal for private circulation




## Introduction — Why the Future of Global Healthcare Needs a New Leader

The healthcare industry is entering one of the most transformative periods in its history. By 2050, biologics, cell and gene therapies, nanotechnology, AI-driven hospitals and 3D bioprinting will be part of daily healthcare. Countries that combine innovation, quality, reliability and scale will shape this future. India, long known as the 'Pharmacy of the World', now has an opportunity to move from volume leadership in generics to value leadership in global healthcare.

### Global Pharma Market Outlook (2024–2050)

In 2024, the global pharmaceutical market is estimated around USD 1.7 trillion. By 2050, it is expected to cross USD 5 trillion, driven by ageing populations, chronic disease burden, and widespread adoption of biologics and advanced therapies.


Figure 1: Global Pharmaceutical Market 2024 vs 2050 (Illustrative).



Every major segment grows in absolute terms, but the value mix shifts strongly towards high-complexity, high-value therapies. The next figure shows how broad segments are expected to evolve.



Figure 2: Market by Segment — 2024 vs 2050 (Illustrative, USD Trillion).




- Small-molecule generics grow in volume but face continued price pressure.
- Biologics and advanced therapies grow fastest and capture a much larger share of value.
- APIs and high-potency APIs remain strategically important as countries diversify supply chains.

### Therapy Areas and Growth Hotspots

Oncology, immunology, diabetes/metabolic disease, cardiovascular disease, vaccines, and neurology/CNS already account for the bulk of pharma spending. By 2050, they grow significantly in absolute size, but oncology, immunology and neurology in particular expand their share thanks to innovation.




Figure 3: Key Therapy Areas — 2024 vs 2050 (Illustrative, USD Trillion).



In the nearer term (2024–2030), oncology and immunology are expected to see low double-digit CAGR, while vaccines, diabetes and neurology grow in high single digits. Cardiovascular lags but remains large in absolute value.

Figure 4: Illustrative CAGR by Major Therapy Area (2024–2030).




### Regional Shifts: Rise of Asia-Pacific

In 2024, North America and Europe together account for roughly three-quarters of global pharma spending. By 2050, Asia-Pacific’s share is expected to rise sharply, driven by China and India, while North America’s relative share moderates and Europe’s declines slightly.



Figure 5: Regional Share of Global Pharma Market — 2024 vs 2050 (Illustrative).



- Asia-Pacific could account for roughly one-third of global pharma spend by 2050.
- North America still grows in absolute terms but loses some share as other regions expand faster.
- Europe’s share shrinks modestly under continued pricing pressure.
- Latin America, Middle East and Africa expand from a low base.

### From Volume to Value: India’s Strategic Roadmap

To lead in this new landscape, India must move beyond low-cost manufacturing of generics and become a trusted, innovation-driven, quality-obsessed partner.

Four pillars define this journey: (1) Indian pharma companies, (2) universities and research institutes, (3) regulators, and (4) government and policy.

#### Pillar 1 – Indian Pharma Companies: From Manufacturers to Innovators

- Invest deeply in biologics, biosimilars, high-potency APIs and selected advanced therapies.
- Make quality cultural, with zero tolerance for data-integrity lapses.
- Increase R&D spend and pursue bold innovation bets.
- Build global brands of trust so that 'Made in India' signals safety, efficacy and reliability.

#### Pillar 2 – Universities & Institutes: From Teaching to Discovery

- Modernize curricula to include gene editing, AI in drug discovery, nanotech and advanced biologics.
- Create joint industry–academia labs and incubators.



- Establish national centers of excellence in key research areas.
- Train a large pool of world-class scientists and clinician–researchers by 2050.

#### Pillar 3 – Regulators: From Gatekeepers to Global Enablers

- Digitize and streamline approvals while maintaining rigor.
- Develop clear pathways for biosimilars, cell and gene therapies and digital therapeutics.
- Participate actively in global harmonization efforts and become a regulator whose decisions are respected worldwide.

#### Pillar 4 – Government: From Supporter to Architect

- Launch a National Healthcare Innovation Mission with clear targets and funding.
- Invest in biotech and advanced therapy parks with shared infrastructure.
- Use policy and diplomacy to build the 'Made in India' healthcare brand as a symbol of quality and innovation.

### **Conclusion — India's Future is a Choice**

The technologies that will define 2050 are already emerging. Whether India becomes a creator of this future or just a consumer depends on the choices we make now.

If India elevates quality, builds scientific depth, reforms regulation and invests boldly in innovation,

it can move from being the Pharmacy of the World to the Heart of Global Healthcare by 2050.